Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 14,816,169 shares, a growth of 2.7% from the April 15th total of 14,433,050 shares. Currently, 12.5% of the company’s stock are sold short. Based on an average daily trading volume, of 857,572 shares, the short-interest ratio is presently 17.3 days.
Shares of NYSEAMERICAN CVRS traded down $0.05 during midday trading on Tuesday, hitting $2.62. 25,457 shares of the stock traded hands, compared to its average volume of 1,182,631. Corindus Vascular Robotics has a one year low of $0.70 and a one year high of $3.10.
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) last released its quarterly earnings results on Tuesday, May 7th. The medical equipment provider reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). The firm had revenue of $3.04 million for the quarter, compared to the consensus estimate of $2.90 million.
A number of institutional investors have recently made changes to their positions in the stock. Weiss Asset Management LP bought a new position in Corindus Vascular Robotics in the 1st quarter worth $65,000. Schonfeld Strategic Advisors LLC raised its holdings in Corindus Vascular Robotics by 12.5% during the first quarter. Schonfeld Strategic Advisors LLC now owns 1,800,000 shares of the medical equipment provider’s stock valued at $3,132,000 after acquiring an additional 200,000 shares during the period. Morgan Stanley raised its holdings in Corindus Vascular Robotics by 5.3% during the first quarter. Morgan Stanley now owns 422,217 shares of the medical equipment provider’s stock valued at $735,000 after acquiring an additional 21,289 shares during the period. Jefferies Group LLC bought a new stake in Corindus Vascular Robotics during the first quarter valued at about $85,000. Finally, ExodusPoint Capital Management LP raised its holdings in Corindus Vascular Robotics by 158.1% during the first quarter. ExodusPoint Capital Management LP now owns 210,127 shares of the medical equipment provider’s stock valued at $366,000 after acquiring an additional 128,727 shares during the period.
Separately, Zacks Investment Research downgraded Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th.
TRADEMARK VIOLATION WARNING: “Short Interest in Corindus Vascular Robotics Inc (CVRS) Rises By 2.7%” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/21/short-interest-in-corindus-vascular-robotics-inc-cvrs-rises-by-2-7.html.
Corindus Vascular Robotics Company Profile
Corindus Vascular Robotics, Inc designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures.
See Also: What is a balanced fund?
Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.